A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA) - Bischoff, Joachim; Barinoff, Jana; Mundhenke, Christoph; Bauerschlag, Dirk Olaf; Costa, Serban-Dan; Herr, Daniel; Lübbe, Kristina; Marmé, Frederik; Maass, Nicolai; Minckwitz, Gunter von; Grischke, Eva-Maria; Müller, Volkmar; et al. (Anti-cancer drugs, 2019)
Gesehen am 08.05.2019